Get the Stockscreener App
2.3294
5.06%
-0.1406
Zentalis Pharmaceuticals Inc stock is traded at $2.3294, with a volume of 187.16K.
It is down -5.06% in the last 24 hours and up +4.22% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
See More
Previous Close:
$2.47
Open:
$2.54
24h Volume:
187.16K
Relative Volume:
0.11
Market Cap:
$176.03M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.5131
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
-3.50%
1M Performance:
+4.22%
6M Performance:
-28.94%
1Y Performance:
-82.83%
1-Day Range:
$2.315
$2.59
1-Week Range:
$2.315
$2.635
52-Week Range:
$1.61
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.325 | 176.03M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.75 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.56 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.35 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.00 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.91 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - PR Newswire
Zentalis stock plunges to 52-week low, hits $2.16 - MSN
Zentalis Pharmaceuticals' chief medical officer acquires $45,656 in stock - MSN
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.24 Consensus PT from Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Ingmar Bruns Buys 20,000 Shares - MarketBeat
What is Leerink Partnrs' Forecast for ZNTL Q3 Earnings? - MarketBeat
Zentalis Pharmaceuticals' chief medical officer acquires $45,656 in stock By Investing.com - Investing.com Australia
Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4) - Quantisnow
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Hold” by Analysts - Defense World
Q1 Earnings Estimate for ZNTL Issued By Leerink Partnrs - MarketBeat
What is Leerink Partnrs’ Estimate for ZNTL Q3 Earnings? - Defense World
Zentalis Pharmaceuticals executive sells shares worth $4,475 - MSN
Potential Price Increase for Zentalis Pharmaceuticals Inc (ZNTL) After Recent Insider Activity - Knox Daily
SG Americas Securities LLC Buys 30,240 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Inc’s (ZNTL) Stock: A Week-by-Week Analysis - The News Heater
Zentalis Pharmaceuticals Inc (ZNTL) Stock: A Year of Highs and Lows - The InvestChronicle
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Acquires 60,000 Shares of Stock - MarketBeat
Zentalis pharmaceuticals director Jan Skvarka buys $103,446 in stock - MSN
Analysts Issue Forecasts for ZNTL Q1 Earnings - Defense World
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Stock Falling -30.99% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Purchases $103,200.00 in Stock - Armenian Reporter
Zentalis Pharmaceuticals chief legal officer sells $22,643 in stock - MSN
HC Wainwright Has Bullish Estimate for ZNTL Q1 Earnings - MarketBeat
Zentalis pharmaceuticals officer sells $24,590 in stock - MSN
Zentalis Pharmaceuticals executive sells shares worth $4,475 By Investing.com - Investing.com Australia
FY2024 Earnings Forecast for ZNTL Issued By Leerink Partnrs - MarketBeat
Zentalis Pharmaceuticals Llc Stock: Executives Sell Shares Amid Market Volatility - sharewise
High-Profile Executives Make Bold Moves with Zentalis Pharmaceuticals Stock - TipRanks
Zentalis pharmaceuticals officer sells $24,590 in stock By Investing.com - Investing.com Nigeria
Analysts review Zentalis Pharmaceuticals Inc’s rating - Knox Daily
Zentalis Pharmaceuticals Inc (ZNTL) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) -2.98% Decline Turns Investors Away - Stocks Register
Millennium Management LLC Acquires Significant Stake in Zentalis Pharmaceuticals Inc - GuruFocus.com
Top Executives Show Strong Confidence in Zentalis Pharmaceuticals with Major Stock Buys - TipRanks
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):